BioSpace News Archive

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be participating in upcoming investor and scientific conferences.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced the appointment of James Hassard as chief commercial officer.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that its management will present at the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 15, 2022.

Agenus Inc., an immuno-oncology company with an extensive pipeline of checkpoint antibodies and adjuvants designed to activate immune response to cancers and infections, provided a corporate update and reported financial results for the fourth quarter and full year 2021.

Organovo Holdings, Inc., and BICO announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo’s foundational patent portfolio in 3D bioprinting.

F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that James Sandy has been appointed as Chief Development Officer, effective today.

BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s health services agency, allowing the CardiAMP® Heart Failure Trial to expand into Canada.

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided a business progress and regulatory update.

Daxor Corporation, the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on February 28, 2022, disclosing its schedule of portfolio holdings as of December 31, 2021.

TFF Pharmaceuticals, Inc. and Catalent announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics through the application of TFF Pharmaceuticals’ patented Thin Film Freezing technology.